What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference67 articles.
1. VHL and HIF signalling in renal cell carcinogenesis;Baldewijns;J Pathol,2010
2. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer;Thomas;Nat Med,2006
3. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial;Escudier;Lancet,2007
4. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007
5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimal sequential therapy using tyrosine kinase inhibitors as the 1st-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study;Asian Journal of Urology;2023-03
2. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort;Japanese Journal of Clinical Oncology;2021-01-22
3. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy;Urologic Oncology: Seminars and Original Investigations;2021-01
4. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis;International Journal of Surgery;2020-07
5. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy;Urologic Oncology: Seminars and Original Investigations;2020-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3